The anti-hyperglycemic agents market size is projected to be worth USD 45.8 billion in 2023. The market is likely to surpass USD 72.3 billion by 2033 at a CAGR of 4.7% during the forecast period. The anti-hyperglycemic agents market refers to the market for pharmaceutical drugs or agents used to manage and control high blood glucose levels in individuals with diabetes mellitus. These agents are designed to lower blood sugar levels and help regulate insulin levels in the body.
Diabetes is a chronic metabolic disorder. It is characterized by elevated blood glucose levels, either ineffective utilization of insulin by the body (Type 2 diabetes) or due to insufficient insulin production (Type 1 diabetes). Anti-hyperglycemic agents play a crucial role in the management of diabetes by improving glycemic control, preventing complications, and enhancing overall quality of life for individuals with diabetes.
Other Drivers Propelling the Demand for Anti-Hyperglycemic Agents include:
Challenges for Companies /Manufacturers in the Anti-Hyperglycemic Agents Market:
Opportunities in the Anti-Hyperglycemic Agents Industry:
Latest Trends in the Anti-Hyperglycemic Agents Market:
| Attributes | Details |
|---|---|
| Anti-Hyperglycemic Agents Market Size (2023) | USD 45.8 billion |
| Anti-Hyperglycemic Agents Market Projected Size (2033) | USD 72.3 billion |
| Value CAGR (2023 to 2033) | 4.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2017 to 2022, the global anti-hyperglycemic agents market experienced a CAGR of 4.9%, reaching a market size of USD 45.8 billion in 2023.
From 2017 to 2022, The prevalence of diabetes has been rising in emerging economies, leading to increased market opportunities for anti-hyperglycemic agents. Improvements in healthcare infrastructure, rising disposable incomes, and increasing awareness of diabetes management have contributed to the growth of the market in these regions.
Future Forecast for Anti-Hyperglycemic Agents Industry:
Looking ahead, the global anti-hyperglycemic agent’s industry is expected to rise at a CAGR of 4.7% from 2023 to 2033. During the forecast period, the market size is expected to reach USD 72.3 billion by 2033.
The anti-hyperglycemic agent’s industry is expected to continue its growth trajectory from 2023 to 2033, The prevalence of diabetes is expected to keep increasing globally as a result of a number of reasons, including sedentary lifestyles, poor diets, and an ageing population. The demand for anti-hyperglycemic medications to treat the condition will rise as its prevalence rises.
| Country | The United States |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 21.8 billion |
| CAGR % 2023 to End of Forecast (2033) | 4.5% |
The anti-hyperglycemic agent’s industry in the United States is expected to reach a market size of USD 21.8 billion by 2033, expanding at a CAGR of 4.5%. The United States has a significant prevalence of diabetes, with a large population affected by the condition.
According to the Centers for Disease Control and Prevention (CDC), around 34.2 million people in the USA have diabetes.
This high prevalence drives the demand for anti-hyperglycemic agents for effective diabetes management.
| Country | The United Kingdom |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 2.1 billion |
| CAGR % 2023 to End of Forecast (2033) | 3.9% |
The anti-hyperglycemic agents industry in the United Kingdom is expected to reach a market share of USD 2.1 billion, expanding at a CAGR of 3.9% during the forecast period. The United Kingdom market is projected to growth of the market due to the growing demand for anti-hyperglycemic agents by healthcare professionals about the benefits of using anti-hyperglycemic agents, leading to increased prescription and use.
| Country | China |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 6.6 billion |
| CAGR % 2023 to End of Forecast (2033) | 5.6% |
The anti-hyperglycemic agents industry in China is anticipated to reach a market size of USD 6.6 billion, moving at a CAGR of 5.6%during the forecast period. The anti-hyperglycemic agent’s industry in China is expected to grow prominently due to the increasing government support. The Chinese government emphasis on improving healthcare infrastructure and increasing access to healthcare services is also a significant factor contributing to the growth of the market.
| Country | Japan |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 2.8 billion |
| CAGR % 2023 to End of Forecast (2033) | 4.1% |
The anti-hyperglycemic agents industry in Japan is estimated to reach a market size of USD 2.8 billion by 2033, thriving at a CAGR of 4.1%. The market in Japan is known for its highly innovative pharmaceutical industry, with many leading drug companies either based in or having a significant presence in the country. Hence, there is a high degree of innovation in development of new anti-hyperglycemic agents.
| Country | South Korea |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 1.4 billion |
| CAGR % 2023 to End of Forecast (2033) | 4.9% |
The anti-hyperglycemic agent’s industry in South Korea is expected to reach a market size of USD 1.4 billion, expanding at a CAGR of 4.9% during the forecast period. The private investment and partnerships between domestic and international pharmaceutical companies are also contributing to the growth of the global market. Also, by working together, these partnerships are driving innovation and streamlining the process of regulatory approvals leading to development of new products in market.
Principal Consultant
The biguanides segment dominated the anti-hyperglycemic agents industry with a market share of 43.9% in 2022. This segment captures a significant market share in 2023. These drug is widely used for treatment of type 2 diabetes, which is a chronic condition that affects millions of people around the world. One of the key advantage of these drug is their effectiveness in reducing glucose levels in blood and improving insulin sensitivity, which contributes in growth of the global market.
The retail pharmacies segment dominated the anti-hyperglycemic agents industry with market share of 39.5% in 2022. These pharmacies are often the primary source of medication for patients with diabetes, and they make it easier for patients to access medication that are necessary for the management of their condition
The anti-hyperglycemic agents sector is fiercely competitive, with many companies fighting for market dominance. To stay ahead of the competition in such a circumstance, essential players must employ smart techniques.
Key Strategies Used by the Participants
Product Development
To produce innovative goods that increase efficacy, dependability, and cost-effectiveness, businesses make significant investments in research and development. Product innovation enables companies to stand out from the competition while also meeting the shifting needs of their customers.
Strategic Alliances & Collaborations
Strategic partnerships and alliances with other businesses are regularly formed by major players in an industry to take advantage of each other's advantages and expand their market reach. Through such arrangements, businesses may also obtain access to new technologies and markets.
Expansion into Emerging Markets
The market for anti-hyperglycemic agents is rising quickly in developing nations like China and India. To boost their presence in these regions, major companies are expanding their distribution networks and building regional manufacturing sites.
Acquisitions and mergers
Mergers and acquisitions are frequently used by key players in the anti-hyperglycemic agents business to consolidate their market position, extend their product range, and gain access to new markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Anti-Hyperglycemic Agents Market:
The market is valued at USD 45.8 billion in 2023.
The market is likely to secure a CAGR of 4.5% through 2033.
Regulations and side effects may hinder market growth.
China is predicted to record a CAGR of 5.6% in 2033.
Biguanides dominate the market through 2033 with a CAGR of 8%.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value Added Insights 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug 7.1. Biguanides 7.2. Alpha-glucosidase inhibitors 7.3. Dopamine -D2 Receptor Agonist 7.4. Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor 7.5. Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors 7.6. Sulfonylureas 7.7. Meglitinides 7.8. Others 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Hospital Pharmacies 8.2. Retail Pharmacies 8.3. Online Pharmacies 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. Middle East and Africa (MEA) 10. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 11. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. Market Structure Analysis 18. Competition Analysis 18.1. Eli Lilly and Company 18.2. Astellas Pharma Inc. 18.3. Sanofi S.A. 18.4. Janssen Pharmaceuticals 18.5. AstraZeneca 18.6. Boehringer Ingelheim 18.7. Takeda 18.8. Merck And Co. 18.9. Bristol Myers Squibb 18.10. Novartis 18.11. Pfizer 19. Assumptions and Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Anti-Hyperglycemic Agents Market
